...that were both clinically and virologically confirmed during a minimum of nine months of surveillance. Vical...
...trial to treat invasive aspergillosis, which could support a limited use indication approval from FDA. Vical...
...Product (QIDP), Orphan Drug and Fast Track designations in the U.S. to treat invasive aspergillosis. Vical...

...infection. VCL-HB01 missed the primary endpoint of reducing the annualized lesion recurrence rate vs. placebo. Vical...
...trial to treat invasive aspergillosis, which could support a limited use indication approval from FDA. Vical...
...Product (QIDP), Orphan Drug and Fast Track designations in the U.S. to treat invasive aspergillosis. Vical...

...Astellas Pharma Inc. (Tokyo:4503) and partner Vical Inc. (NASDAQ:VICL) said cytomegalovirus (CMV) vaccine ASP0113 missed the primary...
...transplant patients receiving an organ from a CMV-seropositive donor (see BioCentury, Sept. 26, 2016 ). Vical Inc....
...antiviral therapy for CMV end-organ disease Status: Phase III data Milestone: NA Jaime De Leon ASP0113 VCL-CB01 Astellas Pharma Inc. Vical Inc. Human...

...Astellas Pharma Inc. (Tokyo:4503) and partner Vical Inc. (NASDAQ:VICL) said cytomegalovirus (CMV) vaccine ASP0113 missed the primary...
...secondary endpoints in the Phase III HELIOS trial in CMV-seropositive allogeneic stem cell transplant recipients. Vical...
...patients receiving an organ from a CMV-seropositive donor (see BioCentury Extra, Sept. 19, 2016) . Vical’s...

...$37.5 NA $60.6 NA RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) 11/8/17 $22.5 $116.9 $109.3 -7% Vical Inc....

...CLL and small cell lymphocytic lymphoma (SLL); relapsed or refractory follicular lymphoma Submit NDA 1Q18 Vical Inc....

...A) Naval Medical Research Center tested formulations both with and without Vaxfectin adjuvant technology from Vical Inc....

...In April, Vical Inc. (NASDAQ:VICL) completed enrollment of 225 adults with symptomatic genital herpes simplex virus type...
...endpoints include safety, time to first recurrence and proportion of patients who are recurrence free. Vical...
...encoding the HSV-2 glycoprotein D and tegument protein VP11/12 (UL46) formulated with Vaxfectin lipid adjuvant. Vical Inc....

...infection through week 24 in HSCT recipients in the Phase III SUPPRESS trial. ASP0113 from Vical Inc....

...evaluate 1 mL intramuscular VCL-HB01 every 28 days for 4 doses in about 225 patients. Vical Inc....